+62.2%
GSK vs RY
+154.9%
-92.6%
-28.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | RY | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.9% | -0.7% | -1.2% | -1.7% |
| 7D | -1.8% | +3.1% | -4.9% | -2.8% |
| 30D | -2.2% | -0.3% | -1.9% | -2.2% |
| 3M | -1.8% | +8.7% | -10.5% | -4.7% |
| 6M | -10.6% | +28.5% | -39.1% | -18.0% |
| YTD | +4.4% | +25.1% | -20.7% | -3.6% |
| 1Y | +30.4% | +46.3% | -15.9% | +14.2% |
| All | +62.2% | +154.9% | -92.6% | +22.7% |
Cumulative growth
Daily Returns
Daily percentage return beside RY.
Daily Out/Under-Performance
Portfolio return minus RY return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × RY return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded RY wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling